This clinical trial is focused on studying the effects of a medication called amlitelimab in people aged 12 years and older who have moderate to severe atopic dermatitis, commonly known as eczema. Atopic dermatitis is a skin condition that causes red, itchy, and inflamed skin. The study is designed for participants who have not responded well to previous treatments, such as biologic therapies or oral medications known as Janus Kinase (JAK) inhibitors. Participants will continue using their usual topical treatments, like corticosteroids, which are creams or ointments applied to the skin to reduce inflammation.

The purpose of the study is to evaluate how effective and safe amlitelimab is when given as a subcutaneous injection, which means it is injected under the skin. The study will compare the effects of amlitelimab to a placebo, which is a substance with no active medication. Participants will be randomly assigned to receive either amlitelimab or the placebo. The study will last for a period of 36 weeks, during which participants will receive regular injections and attend scheduled visits to monitor their progress and any changes in their condition.

Throughout the study, researchers will assess various aspects of the participants’ skin condition, including the severity of eczema symptoms and the overall impact on their quality of life. The study aims to provide valuable information on whether amlitelimab can offer a new treatment option for those with moderate to severe atopic dermatitis who have not found relief with other therapies. Participants will be closely monitored for any side effects or adverse reactions to ensure their safety during the trial.